AlloSource received FDA 510(k) clearance to market AceConnex Pre-Sutured Fascia for hip labral reconstruction and augmentation.
AceConnex is intended for use as a component in soft tissue surgical procedures where constructs, including those with allograft tissue, are used for reconstruction, replacement or augmentation of the labrum. The ready-to-use, sterile device will be available in multiple pre-sutured sizes, with trimmable regions that allow for allograft adjustments to match patients’ anatomy. In addition, AceConnex Pre-Sutured Fascia is manufactured to ensure consistency and minimize variability compared to allografts that are manually sutured pre-operatively.
“AceConnex Pre-Sutured Fascia is integral to our mission of providing innovative allografts to advance patient healing,” said Dean Elliott, AlloSource President and CEO. “We are proud to be first to market with an FDA-cleared pre-sutured fascia device to meet the varying needs of hip arthroscopists and patients.”
AlloSource received FDA 510(k) clearance to market AceConnex Pre-Sutured Fascia for hip labral reconstruction and augmentation.
AceConnex is intended for use as a component in soft tissue surgical procedures where constructs, including those with allograft tissue, are used for reconstruction, replacement or augmentation of the labrum. The...
AlloSource received FDA 510(k) clearance to market AceConnex Pre-Sutured Fascia for hip labral reconstruction and augmentation.
AceConnex is intended for use as a component in soft tissue surgical procedures where constructs, including those with allograft tissue, are used for reconstruction, replacement or augmentation of the labrum. The ready-to-use, sterile device will be available in multiple pre-sutured sizes, with trimmable regions that allow for allograft adjustments to match patients’ anatomy. In addition, AceConnex Pre-Sutured Fascia is manufactured to ensure consistency and minimize variability compared to allografts that are manually sutured pre-operatively.
“AceConnex Pre-Sutured Fascia is integral to our mission of providing innovative allografts to advance patient healing,” said Dean Elliott, AlloSource President and CEO. “We are proud to be first to market with an FDA-cleared pre-sutured fascia device to meet the varying needs of hip arthroscopists and patients.”
Copy to clipboard 
